Document k66K659m9jxQOdzGOkG0z9OeD

738 aM CCoorrppoorraatt IHenauthrPlhysHiycgsiene & CroorproaptsoerOcceupOcrupaationtaiontMedicneMedicne -- May 15,2000 32M0BCooxn3e22B0ung2025.02FY, (] 7 6615510i0y - I-A0R1s2060--00133778s F=al C0 v00(37 PRPeTcaeyreinc BStecoomo0R mis Ai 1 Document Processing Center (Mail Code 7407) Information Management Division UOfnfiitceedofStPaotlsluEtnivoinrPornemveennttailonPraontdecTtoixoincAsgency 4M0Str1 eet, SW : 72 35 9 Room 699 East Tower %( i A`Wtams:hiFnYgIton, D. C. 20460 Ena gg * Dear Sir/Madam: `This submission is being made per the phone conversation between Terry O'Brien (EPA) `sapnedciDfaicntHoaxikceoslo(g3icMa)losntuMdya.y11w0o,u2l0d00l.keTetrorcyonrfeqiuremsttehadtaponrotni-ocnosnfoifdtehneti"aElxpvelrosriaotnoorfy 2a8DFoalyloOrwaeld Tboyxiaci1t4y/2S8t-uDdayywRietcho(vvearryioPuesrfiloud"o,ropclhuesmitchaelass)soBcyiaDtaeidllyaGboarvaatgoreyirnetphoertRat submitted to Dr. Charles Aueron May 4, 2000 is considered TSCA Confidential Business Information. va -E . - Attached for your review is a new copyof the above mentioned study to be included with ha the submittal on perfluorooctane sulfonates made by 3M to Dr. Charles Auer dated May 4,2000. Attached to this letter is a complete non-confidential report with the TSCA CwointfhitdheentTiaSlCBAusCiBnIesisncIlnufdoerdmaatnidonhirgehdlacitgehdt.ed.In a separate envelope is the same report GVery tlty"2y.ourSs, ito) JohnL. ButePh.nD.h ,C.o LH,fD.f AB.,T. Manager, Corporate Toxicology Corporate Toxicology 3M Medical Department Building 220-2E-02 g2<382 z2 5 28 5 = >